Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eden

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cell and Tissue Research|June 16, 2021
Nanobodies: new avenue to treat kidney diseaseNicola Wanner, Thomas Eden, Nastassia Liaukouskaya, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 1, 2022
High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1Maria Kuzikov, Jannis Woens, Andrea Zaliani, et al.
Plos One|September 7, 2017
The role of ADAM17 in the T-cell response against bacterial pathogensMoritz Andreas Link, Karsten Lücke, Joanna Schmid, et al.
Journal of Geophysical Research. Space Physics|November 25, 2024
GOES-R Series X-Ray Sensor (XRS): 1. Design and Pre-Flight CalibrationThomas N Woods, Thomas Eden, Francis G Eparvier, et al.
Frontiers in Immunology|February 8, 2018
A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native ConformationThomas Eden, Stephan Menzel, Janusz Wesolowski, et al.
Immunity, Inflammation and Disease|May 12, 2021
A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike proteinJulia Hambach, Tobias Stähler, Thomas Eden, et al.
Molecular Neurobiology|May 6, 2020
Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER TranslocationBehnam Mohammadi, Luise Linsenmeier, Mohsin Shafiq, et al.
Mabs|June 10, 2026
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumorsWelbeck Danquah, Mélanie Pichery, Thomas Eden, et al.
Allergy|February 2, 2026
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing CellsConstantin Möller, Julia Hambach, Alessa Zoe Schaffrath, et al.
Nature Communications|June 3, 2024
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoireThomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cell and Tissue Research|June 16, 2021
Nanobodies: new avenue to treat kidney diseaseNicola Wanner, Thomas Eden, Nastassia Liaukouskaya, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 1, 2022
High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1Maria Kuzikov, Jannis Woens, Andrea Zaliani, et al.
Plos One|September 7, 2017
The role of ADAM17 in the T-cell response against bacterial pathogensMoritz Andreas Link, Karsten Lücke, Joanna Schmid, et al.
Journal of Geophysical Research. Space Physics|November 25, 2024
GOES-R Series X-Ray Sensor (XRS): 1. Design and Pre-Flight CalibrationThomas N Woods, Thomas Eden, Francis G Eparvier, et al.
Frontiers in Immunology|February 8, 2018
A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native ConformationThomas Eden, Stephan Menzel, Janusz Wesolowski, et al.
Immunity, Inflammation and Disease|May 12, 2021
A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike proteinJulia Hambach, Tobias Stähler, Thomas Eden, et al.
Molecular Neurobiology|May 6, 2020
Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER TranslocationBehnam Mohammadi, Luise Linsenmeier, Mohsin Shafiq, et al.
Mabs|June 10, 2026
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumorsWelbeck Danquah, Mélanie Pichery, Thomas Eden, et al.
Allergy|February 2, 2026
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing CellsConstantin Möller, Julia Hambach, Alessa Zoe Schaffrath, et al.
Nature Communications|June 3, 2024
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoireThomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, et al.
Pageof 1